CHHip: Conventional versus hypofractionated high-dose intensity modulated radiotherapy for localised prostate cancer

Bookmark and Share
Published: 14 Feb 2020
Views: 223
Rating:
Save
Prof David Dearnaley - Institute of Cancer Research, London, UK

Prof David Dearnaley speaks to ecancer at the 2020 ASCO GU meeting in San Francisco about the results from the CHHiP trial.

He outlines the background of this study, which aims to investigate the use of conventional versus hypofractionated high-dose intensity modulated radiotherapy for patients with localised prostate cancer.

Prof Dearnaley explains the results achieved from this eight-year follow up, which found that 60Gy/20f is non-inferior to 74Gy/37f.